NF-κB is a critical mediator of BRCA1-induced chemoresistance

Oncogene

Volumn 33, Issue 6, 2014, Pages 713-723

  Harte, M T ^a   Gorski, J J ^a   Savage, K I ^a   Purcell, J W ^b   Barros, E M ^a   Burn, P M ^a   McFarlane, C ^a   Mullan, P B ^a   Kennedy, R D ^a   Perkins, N D ^c   Harkin, D P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

apoptosis; BRCA1; DNA damage; NF kB

Indexed keywords

APOPTOSIS; BRCA1 PROTEIN; CAMPTOTHECIN; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HEK293 CELLS; HUMANS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84893772928     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.10     Document Type: Article

References (37)

1. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11: 138-148.
2. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25: 5854-5863.
3. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78.
4. Mullan PB, Gorski JJ, Harkin DP. BRCA1-a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta 2006; 1766: 205-216.
5. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
6. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1-and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007; 67: 7078-7081.
7. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
8. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
9. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002; 32: 180-184.
10. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-586.
11. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99: 1683-1694.
12. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65: 10265-10272.
13. Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG et al. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-gamma-mediated apoptosis. Oncogene 2005; 24: 5492-5501.
14. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z et al. Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res 2011; 39: 9536-9548.
15. Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 2003; 278: 26333-26341.
16. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102: 257-265.
17. Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 2010; 70: 2538-2547.
18. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-362.
19. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
20. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 2009; 36: 365-378.
21. Sabatel H, Pirlot C, Piette J, Habraken Y. Importance of PIKKs in NF-kappaB activation by genotoxic stress. Biochem Pharmacol 2011; 82: 1371-1383.
22. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-326.
23. Habraken Y, Piette J. NF-kappaB activation by double-strand breaks. Biochem Pharmacol 2006; 72: 1132-1141.
24. Wang J, Jacob NK, Ladner KJ, Beg A, Perko JD, Tanner SM et al. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep 2009; 10: 1272-1278.
25. Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S et al. NF-kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res 2012; 40: 181-195.
26. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE et al. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 2010; 122: 721-731.
27. Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 2000; 83: 1318-1322.
28. McEachern KA, Archey WB, Douville K, Arrick BA. BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. J Cell Biochem 2003; 89: 120-132.
29. Barre B, Perkins ND. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 2007; 26: 4841-4855.
30. Habraken Y, Jolois O, Piette J. Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray. Oncogene 2003; 22: 6090-6099.
31. Schumm K, Rocha S, Caamano J, Perkins ND. Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit. EMBO J 2006; 25: 4820-4832.
32. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002; 39: 608-610.
33. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005; 41: 2304-2311.
34. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
35. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012; 12: 121-132.
36. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400.
37. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319.